We hypothesized that in the absence of PDE3A, another PDE3 isoform, PDE3B, may compensate for velcrin-induced heterotetrameric complex formation and subsequent antineoplastic effects in AML (27). The gene discussed is PDE3A; the disease is acute myeloid leukemia.